ClinicalTrials.gg
CompletedNCT05004337VANISHUpdated Aug 17, 2026

Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies

An observational study in Vanishing Twin, Trisomy 21 and Trisomy 13, sponsored by Natera, Inc.. Completed at 21 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Natera, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
136
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Down Syndrome with a site in United States — 47 open to participants now, 55 under way, 4 of them phase 3. Down Syndrome · United States.

Enrollment
49th of 74
136 · median 433
Started
2021
with 15 others
Observational
74 of 205
13 open now
Registered
138th of 205
by date
Lead sponsor
8 of 205
Natera, Inc.

Among the 205 studies in Down Syndrome with a site in United States, this one is the 49th largest by enrollment of the 74 observational ones that give a count, is one of 16 that started in 2021, is one of 74 observational ones, and was the 138th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

47 of the 205 studies in Down Syndrome with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Down Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to collect blood samples from women carrying a vanishing twin pregnancy to further develop Natera's non-invasive prenatal screening test to provide information about possible chromosomal conditions for the living twin

03

Conditions studied

  • Vanishing Twin
  • Trisomy 21
  • Trisomy 13
  • Trisomy 18
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women carrying a vanishing twin pregnancy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with either ultrasound-documented dizygotic (DZ) twin pregnancy or those whose Panorama Test™ results suggest increased risk for vanishing twin

Exclusion criteria

Exclusion Criteria:

  • Monozygotic twin pregnancy
  • Non twin pregnancy
  • Maternal history of bone marrow or organ transplantation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
136 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Develop a new algorithm and methodology that will measure fetal fraction and distinguish between the DT (demised/non-viable twin) and living twin (LT) in dizygotic twins (DZ) with a single LT.

    A new algorithm will be written to analyze the serial research blood samples to return a fetal fraction of each twin, and identify which twin is the DT verses the LT. The fetal fraction measurement will be a percentage, and it will be measurable, or not measurable for each sample.

    Time frame: 2 years

  2. The accuracy of the new algorithm to determine which of the signals in the Panorama samples correspond to the LT versus the DT.

    Each complete participant in the study will have multiple maternal blood samples collected, and a child buccal swab. This outcome will use genetic analysis to reflect for each participant if the algorithm correctly or incorrectly identified the LT versus the DT. Accuracy, defined as the number of VT pairs correctly identified as the LT and DT, divided by the total number of VT pairs, will be calculated.

    Time frame: 2 Years

Secondary outcomes

  1. The accuracy of the updated algorithm for the assignment of risk for trisomy 21/18/13 for the LT in DZ twins with a single LT.

    If a sufficient number of trisomy 21/18/13 cases are observed among any of the cases, assess the accuracy of the updated algorithm to correctly determine whether the LT or DT is aneuploidy. Point estimates and 95% confidence intervals for the specificity for the aneuploidy algorithm.

    Time frame: 3 Years

07

Study locations

21 sites
  • Center for Fetal Medicine & Women's Ultrasound
    Los Angeles, California 90048, United States
  • Stanford
    Palo Alto, California 94304, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Yale
    New Haven, Connecticut 06511, United States
  • Christiana Care
    Newark, Delaware 19718, United States
  • Emerald Coast ObGyn
    Panama City, Florida 32405, United States
  • University of Kansas
    Kansas City, Kansas 66160, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Beaumont
    Royal Oak, Michigan 48073, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Hackensack
    Neptune City, New Jersey 07753, United States
  • St. Peter's University Hospital
    New Brunswick, New Jersey 08901, United States
  • NYU Long Island
    Mineola, New York 11501, United States
  • NYU Langone
    New York, New York 10022, United States
  • Icahn School of Medicine at Mount Sinai Hospital
    New York, New York 10029, United States
  • Columbia University
    New York, New York 10032, United States
  • Weill Cornell Medicine
    New York, New York 10065, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Lehigh Valley Health Network
    Allentown, Pennsylvania 18103, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Cedar Health Research
    Irving, Texas 75039, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Nov 2023, 28 months.

Of 55 observational studies under Down Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2021
First posted
Aug 13, 2021
StartActual
Jul 22, 2021
Primary completionActual
Nov 29, 2023
CompletionActual
Nov 29, 2023
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05004337
Lead sponsor
Natera, Inc.
Responsible party
Sponsor
First posted
Aug 13, 2021
Start date
Jul 22, 2021
Primary completion
Nov 29, 2023
Completion
Nov 29, 2023
Last update
Aug 17, 2026

Study contacts

Lorraine Dugoff, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion